Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial

The phase 3 FIRST (Frontline Investigation of REVLIMID + Dexamethasone Versus Standard Thalidomide) trial demonstrated that lenalidomide plus low‐dose dexamethasone (Rd) until disease progression (Rd continuous) is an effective treatment option for transplant‐ineligible patients with newly diagnosed...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Lu, Jin, Lee, Jae H., Huang, Shang‐Yi, Qiu, Lugui, Lee, Je‐Jung, Liu, Ting, Yoon, Sung‐Soo, Kim, Kihyun, Shen, Zhi X., Eom, Hyeon S., Chen, Wen M., Min, Chang K., Kim, Hyo J., Lee, Jeong O., Kwak, Jae Y., Yiu, Wai, Chen, Guang, Ervin‐Haynes, Annette, Hulin, Cyrille, Facon, Thierry
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Haematological Malignancy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5324608/
https://ncbi.nlm.nih.gov/pubmed/28106903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14465
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky